- |||||||||| tamoxifen / Generic mfg.
[VIRTUAL] The challenge of SERMs () - Nov 5, 2020 - Abstract #ISGEI2020ISGE-I_505;
The SERMs assessed appear to have antiestrogenic or neutral effects on the breast; Tamoxifen, Raloxifene, and Lasofoxifene have shown antiestrogenic effects in clinical trials; and Bazedoxifene and Ospemifene have shown antiestrogenic effects in preclinical trials but appear to be neutral in clinical trials to date...Another interesting concept would be TSEC, a combination of Bazedoxifene with conjugated Estrogens...There is no breast or endometrial stimulation with treatment, and cardiovascular risk is not increased, and may be an alternative to HT. The rapid developments in molecular biology incorporates enormous possibilities on molecular biology, stem cells, cell biology in concurrence with genomics, functional genomics, genetics, proteomics, makes us optimistic, about the future of different estrogen modulators in not too long term in term.
- |||||||||| Journal: Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. (Pubmed Central) - Apr 16, 2020
Raloxifene prevents and treats osteoporosis and prevents breast cancer, and can be safely combined with vaginal but not systemic estrogen...Ospemifene is approved to treat dyspareunia, with potential benefits on bone and the breast, while lasofoxifene is being developed to treat resistant estrogen receptor-positive breast cancer in women. Estetrol is an estrogen synthesized exclusively during pregnancy by the human fetal liver and initially considered a weak estrogen, but it appears to have dual weak estrogenic/anti-estrogenic features.
- |||||||||| The challenge of SERMs (HALL 3 FISGE) - Feb 20, 2020 - Abstract #ISGE2020ISGE_485;
The SERMs assessed appear to have antiestrogenic or neutral effects on the breast; Tamoxifen, Raloxifene, and Lasofoxifene have shown antiestrogenic effects in clinical trials; and Bazedoxifene and Ospemifene have shown antiestrogenic effects in preclinical trials but appear to be neutral in clinical trials to date...Another interesting concept would be TSEC, a combination of Bazedoxifene with conjugated Estrogens...There is no breast or endometrial stimulation with treatment, and cardiovascular risk is not increased, and may be an alternative to HT. The rapid developments in molecular biology incorporates enormous possibilities on molecular biology, stem cells, cell biology in concurrence with genomics, functional genomics, genetics, proteomics, makes us optimistic, about the future of different estrogen modulators in not too long term in term.
|
